Skip to main content

Together we are beating cancer

Donate now

Cancer type

Showing 12 out of 2908 results
A 3d rendered image of HPV cells

Wales announced changes to their routine cervical screening programme this week, moving from 3 to 5 years. We look at the science behind the switch. Wales announced changes to their routine cervical screening programme this week, moving from 3 to 5 years. We look at the science behind the switch.

by Alice Davies | Analysis | 7 January 2022

7 January 2022

Melanoma cell. Credit: Dr Erik Sahai

The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer. The National Institute for Health and Care Excellence has recommended the use of the immunotherapy drug pembrolizumab (Keytruda) for some adults in England with a type of advanced melanoma skin cancer.

by Harry Jenkins | News | 21 December 2021

21 December 2021

Charlie Swanton, our chief clinician, headed to the world’s most important climate change conference to talk about the links between pollution and lung cancer in never smokers... Charlie Swanton, our chief clinician, headed to the world’s most important climate change conference to talk about the links between pollution and lung cancer in never smokers...

by Phil Prime | In depth | 13 December 2021

13 December 2021

That Cancer Conversation in a white speech bubble with a dark blue background

Dr Ishu Kataria and her team are working out how to get the HPV vaccine to more than 70 million girls and help India 'eliminate' cervical cancer. Dr Ishu Kataria and her team are working out how to get the HPV vaccine to more than 70 million girls and help India 'eliminate' cervical cancer.

by Cancer Research UK | Podcast | 9 December 2021

9 December 2021

This entry is part 4 of 37 in the series That Cancer Conversation
%postcontent%
Lung cancer cell

More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence. More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence.

by Harry Jenkins | News | 1 December 2021

1 December 2021

The role of the nervous system in cancer progression remains largely unexplored. Now, our researchers at the Francis Crick Institute and Cancer Research UK Edinburgh Centre are leaning into the unknown to find out how cancer uses nerve cells and networks to survive and grow. The role of the nervous system in cancer progression remains largely unexplored. Now, our researchers at the Francis Crick Institute and Cancer Research UK Edinburgh Centre are leaning into the unknown to find out how cancer uses nerve cells and networks to survive and grow.

by Joanna Lewin | In depth | 1 December 2021

1 December 2021

An empty hospital hallway

People who survive cancer in childhood have a higher risk of ill health as they grow older, according to new research published in The Lancet Regional Health – Europe. People who survive cancer in childhood have a higher risk of ill health as they grow older, according to new research published in The Lancet Regional Health – Europe.

by Harry Jenkins | News | 22 November 2021

22 November 2021

A photograph of a lady holding a vaccine and needle.

We spoke to Dr Ishu Kataria who works with WHO to prevent the spread of infections like HPV, which causes 99% of cervical cancers worldwide. We spoke to Dr Ishu Kataria who works with WHO to prevent the spread of infections like HPV, which causes 99% of cervical cancers worldwide.

by Lilly Matson | In depth | 17 November 2021

17 November 2021

Lung cancer cells

Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected. Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.

by Harry Jenkins | News | 11 November 2021

11 November 2021